|
|
 |
| |
 Profiles |
| |
| |
 |
| Guy Fiske |
Milton Brown graduated from the University of Alabama, Birmingham with a Ph.D. in synthetic chemistry. He earned his M.D. from the University of Virginia. While studying under Dr. Wayne Broyillette at the University of Alabama, Birmingham, Dr. Brown, developed the tools to use chemistry to tackle biological problems. By his fourth year of graduate school, Dr. Brown realized that he knew how to make drugs and decided to go to medical school to learn a purpose and use for the drugs he was now able to create. After medical school, Dr. Brown earned a postdoctoral fellow position in the Department of Chemistry at Virginia. In 2000, he became an assistant professor of chemistry in the same department.
Dr. Brown is a medicinal chemist who specializes in the design, synthesis, and evaluation of new drugs. He is also the principal investigator of Lombardi Comprehensive Cancer Center's drug discovery laboratory. Dr. Brown is one of the foremost translational drug discovery scientists in the United States today, and his laboratory has evaluated over 1,000 compounds for possible use as therapeutics to treat prostate cancer, leukemia, and epilepsy. His work has resulted in new, pre clinical models, the creation of two start-up companies, and he holds the rights to 16 patents and patent applications. In addition, Dr. Brown has trained more than 10 Ph. D Chemists and Post Docs.
 |
| Guy Fiske |
Guy W. Fiske graduated from Brown University. He also served in the U.S. Navy as a combat officer in the South Pacific during World War II. For 19 years, Mr. Fiske worked at General Electric and became General Manager for the Specialty Materials Operation of the Computer Division. After joining ITT Corporation, he acquired thirty-five businesses worldwide to develop a billion dollar Auto Parts Group, which he ran as a Group Vice President. In 1977, he became Executive Vice President and Director of General Dynamics Corporation. Mr. Fiske joined the Reagan Administration as Undersecretary of the Energy Department in 1981, and one year later was appointed Deputy Secretary of Commerce. In 1984, he started Fiske Associates Inc., acquiring several educational companies that created a new business: Educational Publishing Corporation. This company, which was later taken public and sold to Tribune Co. (Chicago), focused on innovative mathematical education methods for elementary and high school students. Although now retired, Mr. Fiske serves on the Jupiter Medical Center Foundation and Board of Trustees and is a consultant to several investment companies.
 |
| Andrew D. Hamilton |
Andrew D. Hamilton graduated from the University of Exeter (UK.) He earned a master’s degree at the University of British Columbia and a doctorate from Cambridge University. In 1981, Professor Hamilton was appointed an Assistant Professor of Chemistry at Princeton University. He moved to the University of Pittsburgh in 1988, where he was appointed Professor of Chemistry and served as department chair. Professor Hamilton joined the Yale faculty in 1997. He served as chair of the Chemistry Department at Yale from 1999 until 2003, when he became Deputy Provost for Science and Technology. He was named Provost of the University in October, 2004. In 1999, he received the Arthur C. Cope Scholar Award from the American Chemical Society, and in 2004 he was elected a Fellow of the American Association for the Advancement of Science and of the Royal Society. In additional to being Provost, he is currently the Benjamin Silliman Professor of Chemistry and Professor of Molecular Biophysics and Biochemistry. Professor Hamilton’s research interests lie at the interface of organic and biological chemistry, with particular focus on the use of synthetic design for the understanding, mimicry, and potential disruption of biological processes.
 |
| John A. Hickman |
John Hickman received his PhD in organic chemistry in 1971. After a postdoctoral fellowship in the laboratory of Tom Connors at the Institute of Cancer Research, Fulham Road London he had University posts in molecular pharmacology in Liverpool Birmingham and Yale. As part of the Cancer Research Campaign’s (now CRUK) Experimental Chemotherapy group in Birmingham he was the lead pharmacologist for the discovery of the blockbuster drug Temozolomide, now used to treat brain tumors. Moving to Manchester as the Zeneca Professor of Pharmacology in 1990 he had close ties with Astra-Zeneca, managing a joint laboratory, mainly performing apoptosis research. The work of his own laboratory focussed on the role of apoptosis in determining drug sensitivity and resistance and particularly the role of the Bcl-2 family of proteins. He moved to Paris to direct cancer drug discovery at Servier in 2000. He was Chairman of the Gordon Conference on Cancer Chemotherapy in 1996, and has served on several AACR committees, co-chairing three AACR special meetings.
 |
| Donna M. Huryn |
Donna M. Huryn graduated from Cornell University. She earned her doctorate in Organic Chemistry from the University of Pennsylvania. Dr. Huryn joined the Chemistry Department at Hoffmann-La Roche and worked in the areas of anti-cancer, anti-inflammatory, immunology and anti-viral agents. In 1993, she moved to Wyeth Research’s Chemical Sciences Department where she led the CNS Medicinal Chemistry Department in projects targeting MS, Alzheimer’s disease, and depression, among others, and then led the Chemical Sciences Interface Department. Dr. Huryn is currently Associate Director of the Chemistry Core at the Penn Center for Molecular Discovery (University of Pennsylvania), Scientific Advisor to the University of Pittsburgh Center for Chemical Methodology and Library Design, Senior Scientific Fellow at the Pittsburgh Molecular Library Screening Center, and Adjunct Professor of Pharmaceutical Sciences at the University of Pittsburgh. In addition, Dr. Huryn is a consultant to several technology and biotech companies. She has served on a number of local and national committees of the American Chemical Society and is a member of the Editorial Advisory Board of Organic Letters. Dr. Huryn was a member of the NIH Medicinal Chemistry Study Section from 1996 to 2000 and is a frequent ad hoc member of the Drug Discovery, Development and Delivery SBIR Study Section.
 |
| Jeffrey L. Morby |
Jeffrey L. Morby graduated from Stanford University with a degree in engineering. He earned his M.B.A. from Harvard Graduate School of Business. Mr. Morby has held a number of positions within the finance and banking industry, the most important of which include the following: Vice Chairman of American Express Bank, Vice Chairman of Crocker Bank, Group Executive Vice President in charge of Treasury and Investment Banking, member of the Office of the Chairman of the Bank of Boston, and head of all Latin American activities of the Bank of Boston. While living in South America with his family, Mr. Morby was in charge of the Bank of Boston operations, first in Argentina, and then in Brazil.
Mr. Morby is Managing Director of Amarna Corporation, LLC, a privately-held merchant banking company specializing in financing and creating financial institutions. He is also a Director of Horace Mann Educators Corporation, a publicly-traded insurance company providing insurance and investment products to educators. In 1988, Mr. Morby joined Mellon. At Mellon, he ultimately became Vice Chairman in charge of wholesale activities, which encompassed all large commercial lending and international operations, investment banking, trading, and money market activities. In that capacity, he was also chairman of Mellon Bank Europe, chairman of Mellon Capital Markets, chairman of Mellon’s Proprietary Investment Committee, and director of the Boston Company. In 1996, he retired from Mellon Bank Corporation. Currently, he is Chairman of the Cure Alzheimer’s Fund, a charitable foundation financing research directed at finding cures for Alzheimer’s disease. Mr. Morby is also chairman of the Morby Family Charitable Foundation and director of the Andrew and Velda Morby Educational Foundation. He serves on the boards of the Pittsburgh Cultural Trust, Pittsburgh City Theater, as a member of the Council of the World Wildlife Fund, and as a member of the International Advisory Committee of the Municipality of the City of Wuhan.
 |
| Michael Morin |
Mike Morin graduated from University of Massachusetts Lowell. He earned his PhD in Cancer Pharmacology from State University of New York at Buffalo (Roswell Park Graduate Division). Dr. Morin did an NIH postdoctoral fellowship with Professor Alan Sartorelli at the Yale Comprehensive Cancer Center. He then joined the faculty in the Department of Pharmacology and the Lurie Cancer Center, Northwestern University Medical School, where he was also named Director of the Tumor Cell Biology program. Dr. Morin joined Pfizer in 1991. There, he worked as a laboratory supervisor before becoming a manager in the Cancer discovery program in 1992.
Dr. Morin has had a productive career in cancer research, with a long-standing commitment to improving cancer patient care. In his most recent role, Dr. Morin was a Vice President in Pfizer Global R&D, overseeing Antibacterials, Immunology and Cancer drug discovery in Groton, CT. During his 16-year Pfizer career, Dr. Morin’s leadership enabled the elaboration of approximately 40 clinical candidates, the majority of which are still in active development. Most notable among these was Dr. Morin’s direct leadership in the discovery of, and Phase 2 proof-of-concept for, TarcevaTM, a specific small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase (now marketed by Roche-Genentech). Two additional oncology candidates from Dr. Morin’s group, both monoclonal antibodies (anti-CTLA4 and anti-IGF-1R), have also achieved clinical proof-of-concept and are moving through late-stage clinical trials and NDA filings. A fourth product, a small molecule inhibitor of the focal adhesion kinase (FAK), also has recently achieved clinical proof-of-concept. Additionally, Dr. Morin has been a strong proponent of Pfizer’s ongoing commitment to Antibacterials research, and he has been a leader in the integration of Immunology research into both the Antibacterials and Cancer discovery and development portfolios. Pfizer is uniquely positioned with a significant portfolio of immune-enhancement candidates that may enable (for the first time) clinical efficacy with therapeutic cancer vaccines. He also was a major driver of business development and licensing activities in Pfizer’s oncology therapeutic area. Further, Dr. Morin served as the Oncology Research lead to the licensing leadership team, and the in-licensing of the Coley TLR9 agonist for the treatment of solid tumors was a notable recent achievement.
In his current role, Dr. Morin is leading a start-up in the biotechnology sector- Oncovia Therapeutics, Inc., which will seek to bring effective targeted therapeutics to childhood and adult cancers currently under-served by the drug discovery innovations of the past 10 years. Dr. Morin is a committed supporter of cancer charities at the local and national levels, and he continues to contribute to peer-review of cancer research funding. He also serves as an advisor at UMass Lowell and as an adjunct professor in the School of Pharmacy, University of Rhode Island.
 |
| Homer Pearce |
Homer Pearce graduated from Texas A&M University in 1974 with a bachelor’s degree in chemistry. He earned his doctorate in organic chemistry from Harvard University in 1979, the year he joined Lilly Research Laboratories as a medicinal chemist. Dr. Pearce held several positions of increasing responsibility at Lilly, all of which were focused on the discovery and development of new drugs to treat cancer. He served as Vice President of Cancer Research and Clinical Investigation from 1994-2002 and became a Distinguished Research Fellow, Cancer Research in 2002. Since retiring from Lilly in 2006, Dr. Pearce now serves in several consulting and advisory roles in the academic, government, and biopharmaceutical communities. Dr. Pearce devoted his 27-year career at Lilly to cancer drug discovery and clinical development. His personal research interests included the use of natural products as models to identify new leads for cancer drug discovery and to probe mechanisms of drug resistance. During this time, Lilly’s cancer drug discovery group introduced 25 investigational drugs into clinical trials; three worldwide regulatory agencies including Gemzar and ALIMTA approved three new drugs for the treatment of cancer. A novel protein kinase inhibitor, Enzastaurin, was brought to clinical trials and is now undergoing Phase III trials. Dr. Pearce is a member of the American Association for Cancer Research, the American Chemical Society, the American Association for the Advance of Science, and C-Change. He served as a consultant to the National Cancer Institute and the American Cancer Society, as Vice President and member of the Board of Directors of the Little Red Door Cancer Agency, as a member of the Board of Governors of the Indianapolis Hope Lodge supported by the American Cancer Society, and as a member of the Board of Directors of the American Cancer Society Foundation, Great Lakes Region. In 2001, Dr. Pearce was named a Distinguished Graduate of the College of Science, Texas A&M University, and in 2006 he was named a Hero of Chemistry by the American Chemical Society.
 |
| Raymond Ruddon |
Raymond W. Ruddon graduated summa cum laude from the University of Detroit with a bachelor’s degree in chemistry. He has a doctorate in Pharmacology and an M.D. from the University of Michigan. Dr. Ruddon has authored over 100 scientific papers and five books. One of these, Cancer Biology, now in its third edition, is a widely used text in the field of oncology. He was also co-editor of the classic textbook in pharmacology, Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Dr. Ruddon joined the faculty of the University of Michigan as an Assistant Professor. He was a Professor of Pharmacology before leaving in 1976 to become Director of the Biological Markers Program at the National Cancer Institute. Dr. Ruddon returned to the University of Michigan as the Maurice H. Seevers Professor of Pharmacology and Chair of the Department of Pharmacology from 1981-1990. He also served as the Associate Director for Basic Science Research of the University’s Comprehensive Cancer Center. He received the Distinguished Faculty Achievement Award from the University of Michigan in 1988. In 1990, he became a member of the faculty of the University of Nebraska Medical Center, where he was the Eppley Professor of Oncology and Director of the UNMC Eppley Cancer Center. Dr. Ruddon was Corporate Director of Science & Technology at Johnson & Johnson from 1997 to 2000. From 2000-2004, Dr. Ruddon served as Corporate Vice President, Science & Technology, and Chief Scientific Officer of Johnson & Johnson. He also directed the Corporate Office of Science & Technology. He served as Adjunct Professor of Pharmacology at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. Dr. Ruddon was appointed Senior Associate Dean at the University of Michigan School of Medicine on June 1, 2004, until his retirement in 2007. His responsibilities included guiding the School in decisions regarding emerging fields of science and technology, managing the research space portfolio, and overseeing research compliance activities. Dr. Ruddon’s research has focused on the biosynthesis, protein folding, assembly, and secretion of glycoprotein hormones. Using human chorionic gonadotropin (hCG) as a model, his laboratory was the first to demonstrate the folding pathway of a human protein inside an intact cell.
 |
| Chris H. Takimoto |
Chris H. Takimoto graduated from Stanford University in 1979 with a bachelor’s degree in chemistry. He received both his doctorate in Pharmacology and his M.D. from Yale University in 1986. In 1989, after finishing residency training in Internal Medicine at the University of California, San Francisco, Dr. Takimoto moved to Bethesda, Maryland. He completed a fellowship in Medical Oncology at the National Cancer Institute in 1993 and another fellowship in Clinical Pharmacology at the Uniformed Services University of the Health Sciences in 1996. From 1996 to 2000, he served as a Senior Investigator in the Developmental Therapeutics Department in the Medicine Branch at the National Cancer Institute and as an Assistant Professor of Medicine in the Division of Clinical Pharmacology at the Uniformed Services University.[Takimoto, Chris [CNTUS]] From 2000 to 2007 he was a faculty member of the Dvision of Medical Oncology at the University of Texas Health Science Center in San Antonio and he was also the Director of Pharmacology at the Institute for Drug Development at the Cancer Therapy & Research Center. In 2008 Dr. Takimoto became the head of Translational Medicine as a Senior Director at Ortho Biotech Oncology Research & Development, a member of the Johnson & Johnson family of companies. Dr. Takimoto is also an Adjunct Professor of Pharmacology at the UTHSCSA. Dr. Takimoto's research interests include the pharmacology of new anticancer agents in clinical development, oncology drug development, pharmacokinetics and pharmacodynamics, Phase I clinical trials, and novel treatments for gastrointestinal malignancies. He has published over 125 research articles, reviews, editorials, and book chapters and has served on the editorial board of the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Investigational New Drugs, and several other oncology publications.
 |
| Robert Zivin |
Robert Zivin graduated from Northern Illinois University with a bachelor’s degree in biology. He earned his doctorate in microbiology from the University of Chicago. Subsequently, Dr. Zivin completed a postdoctoral fellowship at the National Cancer Institute. He is currently Corporate Director in the Corporate Office of Science & Technology (COSAT). Dr. Zivin joined Johnson & Johnson in 1986 as a senior scientist at Ortho Diagnostic Systems, Inc. (today’s OCD). Additionally, Dr. Zivin was a member of the team that brought the first DNA probe-based, colorimetric assay to FDA approval. He joined the Biotech Division of the R.W. Johnson Pharmaceutical Research Institute (today’s J&J PRI) in 1989, where he led the Antibody Humanization Project. Several of the molecules (huOKT3, huOKT4A, hu-anti-Tissue Factor) produced in that effort are, or have been, the subject of clinical or pre-clinical development. In 1995, Dr. Zivin established the Exploratory Technology team in RWJ PRI; he was also responsible for the evaluation and development of new discovery technologies. He joined COSAT in 2003. Prior to Johnson & Johnson, Dr. Zivin was a Senior Research Scientist at Merck, Sharpe & Dohme Research Laboratories. While there, he led the team that cloned the first cardiac atrial peptide (ANF).
|
| |
| |
to top |
|
|
| |
| |
|
